(Q40694055)

22 September 2017

1 reference

title

Review: clinical opportunities provided by the nasal administration of peptides (English)

1 reference

22 September 2017

Harris AS

1

1 reference

22 September 2017

publication date

1 January 1993

1 reference

Journal of Drug Targeting

22 September 2017

published in

1 reference

22 September 2017

volume

1

1 reference

22 September 2017

issue

2

1 reference

22 September 2017

page(s)

101-116

1 reference

Distribution and removal of human serum albumin-technetium 99m instilled intranasally

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10611869308996066

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10611869308996066

Prevention of the Dawn phenomenon (early morning hyperglycemia) in insulin-dependent diabetes mellitus by bedtime intranasal administration of a long-acting somatostatin analog.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10611869308996066

Characterization of the barrier properties of mucosal membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10611869308996066

Synthetic thyrotropin releasing factor as a test of pituitary thyrotropin reserve

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10611869308996066

Effects of intranasal insulin in non-obese type II diabetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10611869308996066

Nasal absorption of insulin: enhancement by hydrophobic bile salts

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10611869308996066

Effect of Viscosity on Particle Size, Deposition, and Clearance of Nasal Delivery Systems Containing Desmopressin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10611869308996066

Intranasal recombinant alfa-2b interferon treatment of naturally occurring common colds

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10611869308996066

Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10611869308996066

Intranasal desmopressin (DDAVP) by spray in mild hemophilia A and von Willebrand's disease type I.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10611869308996066

Effects of sodium taurodihydrofusidate on nasal absorption of insulin in sheep

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10611869308996066

Mechanism of Plasminogen Activator and Factor VIII Increase after Vasoactive Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10611869308996066

1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10611869308996066

Dose-dependent inhibition of pituitary-ovarian function during administration of a gonadotropin-releasing hormone agonistic analog (nafarelin).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10611869308996066

Insulin administered intranasally as an insulin-bile salt aerosol. Effectiveness and reproducibility in normal and diabetic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10611869308996066

Effect of salcatonin given intranasally on early postmenopausal bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10611869308996066

Intranasal drug delivery. Potential advantages and limitations from a clinical pharmacokinetic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10611869308996066

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10611869308996066

Intranasal aerosolized insulin. Mixed-meal studies and long-term use in type I diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10611869308996066

Comparative study of intravenous, nasal, oral and buccal TRH administration among healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10611869308996066

Influence of growth hormone on overnight insulin requirements in insulin-dependent diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10611869308996066

Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10611869308996066

Intranasally administered interferon as prophylaxis against experimentally induced influenza A virus infection in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10611869308996066

The effect of intravenous, subcutaneous, and intranasal GH-RH analog, [Nle27]GHRH(1-29)-NH2, on growth hormone secretion in normal men: dose-response relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10611869308996066

Effects of Glypressin on Human Nasal Mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10611869308996066

10.3109/10611869308996066

21 January 2018

Identifiers

DOI

1 reference

22 September 2017

1 reference